GSK cautious on 2018, as drug competition looms, after Q4 beats

LONDON (Reuters) - GlaxoSmithKline said on Wednesday its earnings could slip this year, after a better-than-expected performance in the fourth quarter, as the drugmaker faces increased competition in its core respiratory and HIV businesses.